A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed

Abstract Background Crizotinib is the approved treatment for advanced non-small cell lung cancers (NSCLCs) of anaplastic lymphoma kinase (ALK) fusion. Failure of crizotinib treatment frequently involves drug intolerance or resistance. Comparison of using second-generation ALK inhibitors in this sett...

Full description

Bibliographic Details
Main Authors: Chih-Hsi Scott Kuo, Pi-Hung Tung, Allen Chung-Cheng Huang, Chin-Chou Wang, John Wen-Cheng Chang, Chien-Ying Liu, Fu-Tsai Chung, Yueh-Fu Fang, Yi-Ke Guo, Cheng-Ta Yang
Format: Article
Language:English
Published: BMC 2021-03-01
Series:BMC Cancer
Subjects:
ALK
Online Access:https://doi.org/10.1186/s12885-021-08005-1